AbbVie (ABBV) Non-Current Assets (2012 - 2026)

AbbVie (ABBV) has reported Non-Current Assets for 15 consecutive years, with $101.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 6.0% year-over-year to $101.4 billion in Q2 2026; TTM through Jun 2026 was $414.6 billion, a 6.11% decrease from a year earlier, with the FY2025 full-year figure at $104.9 billion, down 4.27% from the prior year.
• Non-Current Assets was $101.4 billion for Q2 2026 at AbbVie, down from $102.9 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $116.7 billion in Q1 2022 and troughed at $101.4 billion in Q2 2026.
• A 5-year average of $108.1 billion and a median of $108.1 billion in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets climbed 12.27% in 2024 and retreated 8.89% in 2025, its largest moves.
• Over 5 years, Non-Current Assets stood at $110.3 billion in 2022, then dropped by 7.82% to $101.7 billion in 2023, then gained by 7.74% to $109.6 billion in 2024, then retreated by 4.27% to $104.9 billion in 2025, then declined by 3.29% to $101.4 billion in 2026.
• The last three Non-Current Assets figures came in at $101.4 billion (Q2 2026), $102.9 billion (Q1 2026), and $104.9 billion (Q4 2025), per Business Quant data.